Printer Friendly

EMEA pharmaceutical news in briefs.

THE EUROPEAN Medicines Agency (EMEA) has released a guideline on developing, producing, characterising and specifying monoclonal antibodies and related products --http://www.emea.europa.eu/pdfs/human/bwp/15765307enfin.pdf;

* EMEA has also released a draft policy on obtaining practical access to its documents--http://www.emea.europa.eu/pdfs/general/direct/11019606en.pdf;

* This includes a document on accessing its adverse reactions database EudraVigilance--http://www.emea.europa.eu/ pdfs/human/phv/18743906en.pdf.

Other recent EMEA documents include a guideline on the clinical development of medicinal products for the treatment of HIV infection

(http://www.emea.europa.eu/pdfs/human/ewp/63302enfin.pdf); and developing specific immunotherapy products treating allergic diseases

(http://www.emea.europa.eu/pdfs/human/ewp/1850406enfin.pdf).
COPYRIGHT 2009 A long-established global news agency serving specialist publications with foreign news, features, interviews and analysis. See http://www.internationalnewsservices.com for details.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Nuthall, Keith
Publication:International News Services.com
Date:Jan 1, 2009
Words:121
Previous Article:EU researchers use nanoparticles to help drugs target tumuors.
Next Article:Anti-money laundering is become a profession, but a universal model is a far away.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters